DBV Technologies stock rebounds 2.5% with RSI in oversold territory at 29
The French biotech is recovering ground during the session, in an almost stable Paris market. The rebound occurs as the stock remains significantly below its moving averages and three funds maintain short positions on the capital.
A rebound of 2.42% that does not offset the sharp decline of the past month
The DBV Technologies stock gains 2.42% to €2.37 during the session, after closing at €2.31 the previous day. This surge allows it to rank among the strongest gains of the SBF 120, in a broad index virtually unchanged (+0.02%). The movement contrasts sharply with the trajectory of recent weeks: the stock is still down nearly 18% over one month and more than 29% over three months, despite a gain of more than 45% over one year. The price is trading well below its three moving averages.
The 20-day MA at €2.56 represents a gap of -7.42%, the 50-day MA at €2.78 a gap of -14.75%, and the 200-day MA at €3.15 a gap of -24.76%. In this context, today's rebound is taking place from a level close to the €2.31 support, which has been tested repeatedly in recent weeks. The RSI at 29 reflects a marked oversold configuration, consistent with the magnitude of the decline accumulated since spring.
Significant short positions still present and a capital raising program in the background
According to filed declarations, three funds cumulate 3.12% of the capital sold short, a proportion slightly down 0.24 points over thirty days (versus 3.36% a month ago). This level remains elevated and reflects the persistence of institutional downward pressure on the stock, without signaling an acceleration of bearish bets since the last declaration on August 3, 2026. In parallel, the $150 million ATM program filed with the SEC in mid-July gives the company the capacity to raise funds on an ongoing basis on the American market.
This mechanism, which had weighed on the stock at the time of its announcement, remains a underlying parameter for investors monitoring DBV Technologies' financing structure. The next technical inflection point to watch remains the crossing of the 20-day MA at €2.56, which the price has not reached for several weeks.
